Robert W. Duggan
Chief Executive Officer and Chairman of the Board of Directors of Pharmacyclics, Mr. Duggan has been a member of the Board of Directors since September 2007. He served as Chairman of the Board of Directors of Computer Motion, Inc., a computerized surgical systems company, from 1990 to 2003 and Chief Executive Officer from 1997. Computer Motion was acquired by Intuitive Surgical, Inc. in 2003. Mr. Duggan is the Founder of the investment firm Robert W. Duggan & Associates. Mr. Duggan has been a private venture investor for more than 30 years and has participated as a director of, investor in and advisor to numerous small and large businesses in the medical equipment, computer local and wide area network, PC hardware and software distribution, digital encryption, consumer retail goods and outdoor media communication industries. Mr. Duggan has also assisted in corporate planning, capital formation and management for his various investments. He received the Congressman’s Medal of Merit and in 2000 he was named a Knight of the Legion of Honor by President Jacques Chirac. Mr. Duggan is currently also a director of Intuitive Surgical, Inc. He is a member of the University of California at Santa Barbara Foundation Board of Trustees. (1) (3)
Glenn C. Rice, Ph.D.
Glenn Rice, Ph.D. has been involved with the start up and building of seven biotech companies as founder/ member of the early executive management team, which has led to a total of four acquisitions resulting in significantly enhanced shareholder value, and one IPO. He is founder and former CEO of two China-focused companies, Pacific Biopharma Group, Ltd., and Bridge Laboratories, Ltd., which he built to 300 employees and significant revenues. Dr. Rice was the former head of life sciences at SRI International directing over 160 staff, and was the former VP of Research and Board Director of NASDAQ listed ILEX Oncology, which was sold to Genzyme Corp. in 2004 for $1 billion. Prior to ILEX he was a founder and CEO of Convergence Pharmaceuticals, Inc., a Boston-based oncology company; a founder and Director of EmergingMed, an online clinical trial prequalification company; and a past Director and co-founder of C-PATH Institute, a non-profit Institute that is focused on drug development and regulatory innovation. Dr. Rice began his career as a laboratory director at Genentech, and is an inventor on over 20 patents or patent applications, authored over 75 manuscripts and book chapters, and has had extensive experience raising substantial private and public equity and corporate partnerships.
Minesh Mehta, M.D.
Dr. Mehta is an internationally recognized expert in human clinical drug trial strategy, design and execution and has managed national and international trials of all sizes. He is a professor in the Department of Human Oncology at the University of Wisconsin's Paul P. Carbone Comprehensive Cancer Center, and the principal investigator for the Department of Human Oncology program project grant for the first clinical trial of TomoTherapy radiation equipment. Dr. Mehta currently chairs the FDA Radiological Devices Panel and the Brain Tumor Committee in the Radiation Therapy Oncology Group. He serves as a staff physician at eight hospitals in Wisconsin and Illinois, and has authored 70 clinical protocols, over 120 clinical research papers and 30 book chapters. Dr. Mehta obtained his medical degree at the University of Zambia, and completed his residency in radiation oncology at the University of Wisconsin, Madison.
Cynthia Bamdad, Ph.D.
Dr. Bamdad is founder and Chief Scientific Officer of Minerva Biotechnologies, a pioneer in the field of biochips. While a Ph.D. student at Harvard, Dr. Bamdad invented the first electronic DNA chip and the first universal protein chip, and is the sole inventor or co-inventor on over 100 patent applications. Dr. Bamdad has been the principal investigator on grants and contracts from the National Cancer Institute, National Institute for Mental Health, National Science Foundation, Huntington Foundation, National Institute of General Medicine, the Defense Advance Research Projects Agency, and the Advanced Technology Program. She has also given numerous invited talks to institutions worldwide on the topics of cancer research, neurodegenerative diseases, proteomics and biological warfare threat and detection. Dr. Bamdad holds a B.S. in Physics and a Ph.D. in Biophysics from Harvard University.
David Smith, Ph.D
Dr. Smith is a senior biostatistician at City of Hope cancer research hospital in Los Angeles, where he has designed and analyzed over 50 solid tumor and hematology protocols at all levels of development, from pre-clinical and genomic studies to Phase II/III trials. Prior to his tenure at City of Hope, he served as a biostatistical reviewer for the Division of Oncology Drug Products at the U.S. Food and Drug Administration for three years, during which time he reviewed more than 40 chemotherapy INDs and NDAs. Dr. Smith has been a co-investigator on grants from the National Cancer Institute, National Institutes of Health, the American Cancer Society, the Susan G. Komen Breast Cancer Foundation and the Leukemia & Lymphoma Society. He is an author and coauthor of over 40 papers in peer-reviewed biostatistics, oncology, surgery, radiation, and immunology journals. Dr. Smith holds a B.A. in Mathematics and a Ph.D in Statistics.
Jason Adelman
Jason Adelman is Founder and Senior Managing Director of Burnham Hill Partners LLC ("BHP") an investment and merchant banking firm headquartered in New York City. Mr. Adelman has extensive financing and merger and acquisition experience, typically involving complex balance sheets and operational restructurings. Prior to founding BHP, Mr. Adelman was Managing Director of Investment Banking in the New York office of H.C. Wainwright & Company, Inc. Mr. Adelman began his career at Coopers and Lybrand LLP where he worked in the financial services industry consulting practice, with a particular focus on the hedge fund industry. Mr. Adelman is also the co-founder and a Managing Member of Cipher Capital Partners, a private investment entity that has invested, through its managed accounts, approximately $250 million in capital since 2006. Mr. Adelman graduated from the University of Pennsylvania with a BA, cum laude, in Economics (1991) and graduated from Cornell Law School (1994), where he was Editor of the Cornell International Law Journal. Mr. Adelman also serves on the audit and compensation committees of Trio-Tech International, an Amex listed company.
Richard van den Broek
Richard van den Broek joined the Company as a director in March 2008. Since 2004, Mr. van den Broek has been Managing Partner of HSMR Advisors, LLC, an investment fund focused on the biotechnology industry. From 2000 through 2003 he was a Partner at Cooper Hill Partners, LLC, an investment fund focused on the healthcare sector. Prior to that Mr. van den Broek had a ten year career as a biotech analyst, starting at Oppenheimer & Co., then Merrill Lynch, and finally at Hambrecht & Quist. Mr. van den Broek is a graduate of Harvard University and is a Chartered Financial Analyst.
| (1) | Member of the Nominating and Corporate Governance Committee |
| (2) | Member of the Audit Committee |
| (3) | Member of the Compensation Committee |